ArticlePacing and clinical electrophysiology : PACE2026
Jugular Journeys: A Novel Approach for AVEIR Leadless Pacemaker Implantation.
Article in Pacing and clinical electrophysiology : PACE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Jugular Journeys: A Novel Approach for AVEIR Leadless Pacemaker Implantation.Pacing and clinical electrophysiology : PACE · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe jugular approach for Micra leadless pacemaker (LP) implantation offers potential advantages over the femoral route, however data on safety and feasibility for the relatively larger AVEIR LP implantation through the jugular vein is limited. This study evaluated the procedural safety and short-term clinical outcomes of AVEIR ventricular LP implantation via the internal jugular vein (IJV).
methodsAll consecutive patients undergoing AVEIR LP implantation via the IJV at our center between November 2023 and July 2025 were included. Procedural details, device electrical parameters and complications were collected from patient electronic records.
resultsEighteen patients (median age 76 years, 33% female) had an AVEIR LP implantation via the IJV. Implantation was successful in 17/18 patients (94%). The median duration of the procedures was 65.5 min (45.0-134.0) with a median fluoroscopy time of 11.2 min (7.4-42.3). Median follow-up time was 9.9 months (0.6-19.5). During follow up the device electrical parameters remained stable with, mean R-wave amplitude 8.83 mV ± 3.6, pacing threshold 0.75 V. ± 0.4 V and impedance 730 ± 338 Ω; with an average estimated battery longevity of 16.0 ± 4.5 years. Two minor procedural complications occurred: one requiring conversion to femoral access, and one requiring an additional transvenous pacemaker lead due to elevated pacing thresholds. No vascular complications were observed.
conclusionAVEIR ventricular LP implantation via the IJV is safe and feasible, with stable electrical performance, during short-term follow-up. While the larger device size may challenge AVEIR implantations in smaller hearts, using the delivery sheath as a support to create a sharper curve facilitates the procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.